Senti Biosciences (SNTI) said Monday enrollment in the investigator-sponsored trial for SENTI-301A, a treatment for hepatocellular carcinoma, has been paused.
The study is being conducted in partnership with Celest Therapeutics (Shanghai) Co. in China and uses Senti's SENTI-301A gene circuit in Chimeric Antigen Receptor Natural Killer cells manufactured by Celest. The trial was halted after dose-limiting toxicities were observed. Senti Bio is currently evaluating next steps for the program as part of a broader pipeline prioritization effort, the company said.
The company also reported additional preliminary data from its phase 1 trial of SENTI-202, an investigational off-the-shelf CAR-NK cell therapy that is being developed for the treatment of relapsed or refractory hematologic cancers, including acute myeloid leukemia.
In the dose-finding stage, SENTI-202 was well tolerated, with no dose-limiting toxicities reported and no maximum tolerated dose reached, and a preliminary recommended phase 2 dose was identified. The trial is ongoing, with continued enrollment to confirm the preliminary RP2D and expand into disease-specific groups, the company said.
The company also shared preliminary, unaudited financial results for Q1. The company reported a net loss of $14.1 million, or $1.41 per share, for the quarter ended March 31. Final results will be released in its upcoming 10-Q filing, expected around May 6.
Shares of Senti Biosciences fell past 22% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.